GlobeImmune

GlobeImmune, Inc.
Company typePublic
Nasdaq: GBIM
IndustryBiotechnology
FoundedJanuary 1, 1995; 30 years ago (1995-01-01)
Headquarters
Louisville, Colorado
,
United States
Number of employees
22 (Dec 2014)[1]
Websiteglobeimmune.com

GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases.[2] As of August 2014, the company had no marketed products.[3][self-published source] GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.

Tarmogen platform

The company has partnerships with Celgene (established in 2009)[2] and the National Cancer Institute for the development of cancer vaccines.[4][5] Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.[6]

With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.[2]

As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers.[7] Completed trials have addressed two other candidates, GI-4000 (the company's lead oncology candidate as of 2010)[2] and GI-5005.[7] Despite there being three ongoing trials, in July 2015 the company announced it would eliminate "most of its workforce positions" shortly following the failure of a trial examining GI-4774.[1]

In March 2017, GlobeImmune announced that it has entered into a definitive purchase agreement for the sale of shares of its common stock to NantCell, Inc.[8]

References

  1. ^ a b "Industry Watch". Genetic Engineering & Biotechnology News. 35 (13): 8. July 2015. doi:10.1089/gen.35.13.04.
  2. ^ a b c d Staff (19 January 2010). "GlobeImmune Raises $17.5M in Series E Financing". Genetic Engineering & Biotechnology News. Retrieved 2015-08-19.
  3. ^ "About GlobeImmune" (PDF). GlobeImmune. 22 August 2014. Retrieved 2015-08-19.
  4. ^ "GlobeImmune and Celgene Corporation Announce Strategic Global" (Press release). Celgene. 15 May 2009 – via Bloomberg.
  5. ^ Staff (16 April 2009). "GlobeImmune starts cancer drug trial". BizWest. Colorado, United States: BizWest Media.
  6. ^ Adams, Ben (November 18, 2016). "GlobeImmune draws the curtain as Gilead kills drug deal, CEO role abandoned". FierceBiotech.
  7. ^ a b "Search of:globeimmune". ClinicalTrials.gov. United States National Institutes of Health.
  8. ^ "GlobeImmune Announces Majority Stock Sale". www.prnewswire.com (Press release). Retrieved 2020-02-24.